Navigation Links
ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb
Date:10/30/2010

irus at week 4 (defined as Rapid Virological Response, or RVR). Patients are being followed for 24 weeks after stopping therapy to determine the rate of Sustained Virological Response, or SVR. Approximately 90 patients have been enrolled in this study – with approximately 30 patients receiving ANA598 plus SOC at each dose level and 30 patients receiving placebo plus SOC. The study is being managed by the Duke Clinical Research Institute (DCRI) and is being conducted at a number of clinical sites in the United States.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. Anadys is preparing to initiate a Phase IIb study of ANA598, the Company's direct-acting antiviral or DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) the plans and trial design for the planned ANA598 Phase IIb study; (ii) the belief that the preclinical properties of ANA598 support investigation of combinations with other direct antivirals and the ability to pursue such combinations;  (iii) assessments of the potency, safety and tolerability profile of ANA598 based on the 12 week results; (iv) the durability of antiviral response after treatment with ANA598 is conc
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
11. ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 Announced at the 20 th ... agreement seeks to increase access to a promising new HIV ... 2014 conference in Melbourne today, the ... Gilead Sciences for tenofovir alafenamide (TAF), a promising new medicine ... in India and China ...
(Date:7/23/2014)... 2014 Today,s U.S. Food and Drug ... with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma ... significant advance for patients with these blood cancers.  ... trade name Zydelig®, is a first-in-class inhibitor of ... in many B-cell malignancies and plays a critical ...
(Date:7/23/2014)... ALTO, Calif., July 23, 2014  Varian Medical Systems ... earnings of $1.02 per diluted share in the third ... impacted by about $0.06 per diluted share due to ... portion of Varian,s existing equity investment in Augmenix, a ... company-wide revenues totaled $748 million for the third quarter ...
Breaking Medicine Technology:The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 2The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 3The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 10
... Truphatek has successfully enticed one of the best known professionals in ... , Dan White , formerly of ... a new US subsidiary of Truphatek http://www.truphatek.com/ ... I may be reached after this week at 573-240-0002 or by e-mail ...
... , NEWARK, Calif., Oct. 6 Extending its reach ... North America, Inc. has signed ... distribute its perfluoroelastomer sealing components and provide local applications ... are integral in the ultraclean manufacturing of semiconductors, solar ...
Cached Medicine Technology:New Places and People - Truphatek opens USA subsidiary 2New Places and People - Truphatek opens USA subsidiary 3Applied Seals North America Extends Global Network With Addition of Distributor in Europe 2
(Date:7/23/2014)... 24, 2014 The routine use ... greatly increases the likelihood of performing the correct ... cancer, report researchers from the University of Pittsburgh ... The test, available at the UPMC/UPCI Multidisciplinary Thyroid ... chances of patients getting the correct initial surgery ...
(Date:7/23/2014)... Dallas, Texas (PRWEB) July 24, 2014 ... 500 enterprises engaging in the dust-collecting equipment in ... the manufacturing of bag-type dust collectors and remaining ... manufacturing of electrostatic precipitators. At the end of ... collectors in China reached CNY 23.65 billion, accounting ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 The discounts ... and beauty products do not include various skin creams ... now revealing skin tightening cream discounts inside of its ... The guide is now available to offer a direct ... recently released products available for sale. Although the guide ...
(Date:7/23/2014)... The beauty products industry is expected to ... according to recent news reports. Creams and oils to ... the U.S. and the CherryNews.com company is now reviewing ... now reviewed at http://cherrynews.com/best-nourishing-eye-serum . , This in-depth ... shopper to compare the different brands offered from retailers ...
(Date:7/23/2014)... “Unlike most Sales Training Programs, the Sales Success ... gifts, talents and abilities as opposed to giving you ... Marr Brown. It is based on his ... from nearly getting fired for poor sales performance to ... contest offered and taking a last placed sales team ...
Breaking Medicine News(10 mins):Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 2Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 3Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 4Health News:2018 Dust Collecting Equipment Industry in China Major Enterprises Analysis Now Available at MarketReportsChina.com 2Health News:2018 Dust Collecting Equipment Industry in China Major Enterprises Analysis Now Available at MarketReportsChina.com 3Health News:Skin Tightening Cream Discounts Revealed in New Cost Saving Guide at Consumer Portal 2Health News:Best Wrinkle Cream Under $100 Reviewed at Top News Website Online 2Health News:Using Your Story and Not Technique to Achieve Sales Success 2
... ATLANTA , March 17 Stonebranch, the industry ... businesses and Job Scheduling technology , announced today ... Safe Harbor: What the HITECH Act Means for U.S. Healthcare ... recent healthcare regulations and how healthcare organizations (HCOs), related covered ...
... rate is higher with metal staples, review finds , ... common when orthopedic surgeons use metal staples instead of ... , Infections after surgery can lead to longer hospital ... hip replacement. Infected wounds can also cause serious complications. ...
... March 17 Anatomist and Inventor of Plastination, Dr. ... present their new exhibition, BODY WORLDS of ... premiering at the Neunkirchen Zoo in Germany , beginning ... menagerie, the display features the most revered species in the animal ...
... ... extend to visualize all network communications in the enterprise and those extending out to ... ... of a major update to its Versiera Infrastructure Management System, including new groundbreaking technology ...
... ... Health Makeover Contest and announces that they are increasing the amount of smile makeover winners ... ... nation’s foremost voice in unbiased, expert advice on how to care for your smile and ...
... ... Strategic Leadership Development program for its current and potential physician leaders, through New York ... ... participating in a Strategic Leadership Development program for its current and potential physician leaders. ...
Cached Medicine News:Health News:Stonebranch Publishes Healthcare IT White Paper 2Health News:Stonebranch Publishes Healthcare IT White Paper 3Health News:Stonebranch Publishes Healthcare IT White Paper 4Health News:Gunther von Hagens' BODY WORLDS of Animals Opening March 19 at the Neunkirchen Zoo 2Health News:Gunther von Hagens' BODY WORLDS of Animals Opening March 19 at the Neunkirchen Zoo 3Health News:Versiera Enables Cloud and Enterprise Network Visualization 2Health News:Versiera Enables Cloud and Enterprise Network Visualization 3Health News:Dear Doctor Magazine Reveals Makeover Contest Winner's Results and Expands Contest to Include Additional Winners 2Health News:Dear Doctor Magazine Reveals Makeover Contest Winner's Results and Expands Contest to Include Additional Winners 3Health News:Summit Medical Group Prepares Physicians for Future Leadership 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: